| 1 |
Stability of extemporaneously prepared sitagliptin phosphate solution |
|
|
| Abdel Naser Zaid, Yara Abu Zaaror, Aiman Kaddumi, Mashhour Ghanem, Nidal Jaradat, Tharaa Abu Salah, Sameera Siaj, Lana Omari, Girish Sailor |
|
| PLOS ONE. 2022; 17(3): e0262068 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 2 |
Circulating Dipeptidyl Peptidase Activity Is a Potential Biomarker for Inflammatory Bowel Disease |
|
|
| Simone E. Jaenisch, Catherine A. Abbott, Mark D. Gorrell, Peter Bampton, Ross N. Butler, Roger Yazbeck |
|
| Clinical and Translational Gastroenterology. 2022; 13(1): e00452 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 3 |
Synthesis, Characterization and Screening of Some Novel 2-Methyl-N'-
[(Z)-Substituted-Phenyl ethylidene] Imidazo [1, 2-a] Pyridine-3-Carbohy
drazide Derivatives as DPP-IV Inhibitors for the Treatment of Type 2 Diabetes
Mellitus |
|
|
| Prerana A. Chavan, Shailaja B. Jadhav |
|
| Letters in Drug Design & Discovery. 2022; 19(2): 160 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 4 |
HL-7 and HL-10 Peptides Stimulate Insulin Secretion in the INS-1 Insulinoma Cell Line through Incretin-Dependent Pathway and Increasing the Glucose Uptake in L6 Myoblast |
|
|
| Zahra Setayesh-Mehr, Mahdiye Poorsargol |
|
| International Journal of Peptide Research and Therapeutics. 2021; 27(4): 2231 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 5 |
Sitagliptin relieves diabetic nephropathy fibrosis via the MAPK/ERK signaling pathway |
|
|
| Shufeng Cheng, Liang Li, Chunquan Song, Huijing Jin, Shouguo Ma, Ping Kang |
|
| Minerva Endocrinologica. 2020; 45(3) |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 6 |
CRISPR/Cas9 gene editing demonstrates metabolic importance of GPR55 in the modulation of GIP release and pancreatic beta cell function |
|
|
| A.G. McCloskey, M.G. Miskelly, C.B.T. Moore, M.A. Nesbit, K.A. Christie, A.I. Owolabi, P.R. Flatt, A.M. McKillop |
|
| Peptides. 2020; 125: 170251 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 7 |
Alkaloid Fraction of Litsea glutinosa Leaves Provides an Important Precursor for Inhibition of Dipeptidyl Peptidase 4 Activity |
|
|
| S W Kisnawaty, P Nityasewaka, B A R Sukma, A V Putrinadia, T Ma’rifah, D G Tamtomo, D Indarto |
|
| IOP Conference Series: Materials Science and Engineering. 2019; 546(6): 062013 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 8 |
The effect of CD26-deficiency on dipeptidyl peptidase 8 and 9 expression profiles in a mouse model of Crohn's disease |
|
|
| Suncica Buljevic, Dijana Detel, Ester P. Pugel, Jadranka Varljen |
|
| Journal of Cellular Biochemistry. 2018; 119(8): 6743 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 9 |
Compare clinical efficacy between vildagliptin 100 mg and sitagliptin 100 mg in inadequate patients with sitagliptin 50 mg |
|
|
| Kuribayashi, N. |
|
| Therapeutic Research. 2012; 33(5): 703-710 |
|
| [Pubmed] [Google Scholar] |
|
| 10 |
Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): Crossover pilot study (J-VICTORIA study) |
|
|
| Masaya Sakamoto,Rimei Nishimura,Taiga Irako,Daisuke Tsujino,Kiyotaka Ando,Kazunori Utsunomiya |
|
| Cardiovascular Diabetology. 2012; 11(1): 92 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 11 |
Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans |
|
|
| B. Ahrén,A. Schweizer,S. Dejager,E. B. Villhauer,B. E. Dunning,J. E. Foley |
|
| Diabetes, Obesity and Metabolism. 2011; 13(9): 775 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 12 |
Target-mediated metabolism and target-mediated drug disposition of the DPPIV inhibitor AMG 222 |
|
|
| Robert J. Greene,Hua Tu,John P. Gibbs,J. Greg Slatter |
|
| Xenobiotica. 2011; 41(11): 945 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 13 |
Flavonoid rich fraction of Pilea microphylla (L.) attenuates metabolic abnormalities and improves pancreatic function in C57BL/KsJ-db/db mice |
|
|
| P. Bansal,P. Paul,G. Shankar,D. Munjal,P.G. Nayak,K.I. Priyadarsini,M.K. Unnikrishnan |
|
| Biomedicine & Preventive Nutrition. 2011; 1(4): 268 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 14 |
Target-mediated metabolism and target-mediated drug disposition of the DPPIV inhibitor AMG 222 |
|
|
| Greene, R.J., Tu, H., Gibbs, J.P., Greg Slatter, J. |
|
| Xenobiotica. 2011; 41(11): 945-957 |
|
| [Pubmed] [Google Scholar] |
|
| 15 |
Flavonoid rich fraction of Pilea microphylla (L.) attenuates metabolic abnormalities and improves pancreatic function in C57BL/KsJ-db/db mice |
|
|
| Bansal, P., Paul, P., Shankar, G., Munjal, D., Nayak, P.G., Priyadarsini, K.I., Unnikrishnan, M.K. |
|
| Biomedicine and Preventive Nutrition. 2011; 1(4): 268-272 |
|
| [Pubmed] [Google Scholar] |
|
| 16 |
Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans |
|
|
| Ahrén, B., Schweizer, A., Dejager, S., Villhauer, E.B., Dunning, B.E., Foley, J.E. |
|
| Diabetes, Obesity and Metabolism. 2011; 13(9): 775-783 |
|
| [Pubmed] [Google Scholar] |
|
| 17 |
Clinical experience of a selective dipeptidyl peptidase IV inhibitor, vildagliptin |
|
|
| Tomioka, Y. |
|
| Therapeutic Research. 2011; 32(6): 841-849 |
|
| [Pubmed] [Google Scholar] |
|
